|
|
Article: Maxygen Announces New Development Program and Product Development Prioritization.
- Article from:
- PR Newswire
- Article date:
- December 4, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Maxygen, Inc. announced today that it will advance a novel factor VII program into preclinical development and as a part of its ongoing internal portfolio prioritization will terminate development of its interferon beta program.
Maxygen has generated a novel factor VIIa (MAXY-VII) molecule that may provide a more effective treatment for uncontrolled bleeding. In preclinical animal models, MAXY-VII has demonstrated enhanced efficacy and an improved in vivo circulating half-life compared to alternative products. MAXY-VII appears to stimulate more rapid and increased thrombin generation in blood resulting in a significant reduction in blood loss in relevant ...